Search hospitals > Maryland > Bethesda
American Oncology Partners of Maryland, PA
Claim this profileBethesda, Maryland 20817
Global Leader in Lymphoma
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Multiple Myeloma
Conducts research for Plasma Cell Neoplasms
48 reported clinical trials
4 medical researchers
Summary
American Oncology Partners of Maryland, PA is a medical facility located in Bethesda, Maryland. This center is recognized for care of Lymphoma, Lung Cancer, Non-Small Cell Lung Cancer, Multiple Myeloma, Plasma Cell Neoplasms and other specialties. American Oncology Partners of Maryland, PA is involved with conducting 48 clinical trials across 74 conditions. There are 4 research doctors associated with this hospital, such as Mark Goldstein, MD, Ralph Boccia, Bruce D Cheson, and Ralph Vincent Boccia.Area of expertise
1Lymphoma
Global LeaderCD20 positive
MYC positive
Stage II
2Lung Cancer
Stage IV
Stage III
KRAS positive
Top PIs
Mark Goldstein, MDJEM Research Institute4 years of reported clinical research
Expert in Alzheimer's Disease
Studies Colorectal Cancer
28 reported clinical trials
45 drugs studied
Ralph BocciaAmerican Oncology Partners of Maryland, PA11 years of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
16 reported clinical trials
32 drugs studied
Bruce D ChesonAmerican Oncology Partners of Maryland, PA2 years of reported clinical research
Studies Lymphoma
Studies Leukemia
4 reported clinical trials
5 drugs studied
Ralph Vincent BocciaAmerican Oncology Partners of Maryland, PA3 years of reported clinical research
Studies Preleukemia
Studies Syndrome
1 reported clinical trial
2 drugs studied
Clinical Trials running at American Oncology Partners of Maryland, PA
Lymphoma
Non-Hodgkin's Lymphoma
Follicular Lymphoma
Myelofibrosis
Breast Cancer
Non-Small Cell Lung Cancer
Marginal Zone Lymphoma
Myelodysplastic Syndrome
Lung Cancer
Preleukemia
Zanubrutinib + Anti-CD20
for Lymphoma
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
Recruiting2 awards Phase 35 criteria
Epcoritamab + Rituximab + Lenalidomide
for Lymphoma
This trial tests a new drug combination for adults with untreated follicular lymphoma, a type of blood cancer. The new treatment includes epcoritamab, lenalidomide, and rituximab, which work together to help the immune system attack cancer cells. The study will check how safe and effective this combination is. Lenalidomide combined with rituximab has shown high efficacy in both relapsed/refractory and untreated follicular lymphoma.
Recruiting2 awards Phase 310 criteria
Epcoritamab + R-CHOP
for Diffuse Large B-Cell Lymphoma
This trial tests a new drug called epcoritamab combined with a mix of cancer-fighting drugs in adults with a rare type of aggressive cancer called DLBCL. Epcoritamab helps the immune system attack cancer cells, while the other drugs work together to kill them. This combination has been used as the standard treatment for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) for many years.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at American Oncology Partners of Maryland, PA?
American Oncology Partners of Maryland, PA is a medical facility located in Bethesda, Maryland. This center is recognized for care of Lymphoma, Lung Cancer, Non-Small Cell Lung Cancer, Multiple Myeloma, Plasma Cell Neoplasms and other specialties. American Oncology Partners of Maryland, PA is involved with conducting 48 clinical trials across 74 conditions. There are 4 research doctors associated with this hospital, such as Mark Goldstein, MD, Ralph Boccia, Bruce D Cheson, and Ralph Vincent Boccia.